Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
Transcatheter Amplatzer Occlusion and Surgical Closure of Patent Ductus Arteriosus: Comparison of Effectiveness and Costs in a Low-Income Country
Pediatric Cardiology, 04/27/09
Chen Z et al. - Although transcatheter Amplatzer device occlusion is as effective as and less invasive than surgical closure for PDA, surgical closure is less costly. In low-income countries such as China, where health-care resources are limited, PDA closure with the Amplatzer duct occluder device is not cost-effective.
Related Articles
The Elderly Patient and Cardiac Surgery - A Mini-Review
Gerontology, 10/13/09
Relevance Score: 81%
Influence of timing of intraaortic balloon placement in cardiac surgical patients
The Journal of Thoracic and Cardiovascular Surgery, 11/17/09
Relevance Score: 80%
Simplified Management of Hemodialysis-Dependent Patients Undergoing Cardiac Surgery
Annals of Thoracic Surgery, 10/29/09
Relevance Score: 80%
Leucocyte filtration of salvaged blood during cardiac surgery: effect on red blood cell function in concentrated blood compared with diluted blood
European Journal of Cardio-Thoracic Surgery, 10/28/09
Relevance Score: 80%
Atorvastatin increases the number of endothelial progenitor cells after cardiac surgery: a randomized control study
Journal of Cardiovascular Pharmacology, 10/19/09
Relevance Score: 80%
Today in Pharmacoeconomics...keeping you current
Receive free subspecialty "5-minute updates" via email
Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia
Current Medical Research and Opinion, 12/18/09
Costs of hospital-based methadone maintenance treatment in HIV/AIDS control among injecting drug users in Indonesia
Health Policy, 12/16/09
Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
Cost Effectiveness and Resource Allocation, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


